Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 14Gastrointestinal 7Thoracic 5CNS 5Myeloid 3Lymphoid 3Breast 3Sarcoma 2Other hematologic neoplasm 2Head & Neck 2Tumor-Agnostic 1Plasma cell 1Other neoplasm 1NET 1Endocrine 1Dermatologic 1

Conditions

Advanced Lung Neuroendocrine Tumor 1

Interventions

lutetium Lu 177 dotatate 30Magnetic Resonance Spectroscopy 25pembrolizumab 21Specimen Handling 18Nivolumab 17cabozantinib 14lenvatinib 12Everolimus 12trametinib 11gallium Ga 68 dotatate 10dabrafenib 10Ipilimumab 10Carboplatin 10Cisplatin 8atezolizumab 7Temozolomide 7Lutetium-177 7X-Rays 6Etoposide 6Capecitabine 6surufatinib 5lanreotide 5fluorodopa F 18 5cemiplimab 5Vemurafenib 5Paclitaxel 5Octreotide 5Lutetium 5Fluorodeoxyglucose F18 5Disulfides 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Photons × Endocrine × 1 year × Clear all
NCT04665739 2026-05-13

Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors

National Cancer Institute (NCI)

Phase 2 Recruiting
70 enrolled
EndocrineNET

Advanced Lung Neuroendocrine Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡